Who is sponsoring NCT05531162?

NCT05531162 is sponsored by University Hospital, Caen.

What drugs are being tested in NCT05531162?

Interventions in NCT05531162: Cognition and emotional neuropsychologicl evaluations.

What condition does NCT05531162 study?

NCT05531162 studies Body Schema.

Is NCT05531162 still recruiting?

NCT05531162 is currently completed. Last updated 25 July 2025.

Last reviewed 2025-07-25 · How we verify

NCT05531162: ENACT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Body-environment Relationship Related Modified Gravity

Completed NA Last updated 25 July 2025

What this trial tests

NA trial testing Cognition and emotional neuropsychologicl evaluations in Body Schema in 24 participants. Completed in 23 December 2023.

Timeline

23 October 2022

Primary endpoint
26 April 2023

23 December 2023

Quick facts

Lead sponsor	University Hospital, Caen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	24
Start date	23 October 2022
Primary completion	26 April 2023
Estimated completion	23 December 2023
Sites	1 location across France

Drugs / interventions tested

Cognition and emotional neuropsychologicl evaluations

Conditions studied

Body Schema — all drugs for Body Schema →

Sponsor

University Hospital, Caen

Who can join

Adults 18 to 70, any sex, with Body Schema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall objective of this study is to better understand the relationship between the body and its environment, including cognitive performance, following repeated changes in gravity, including microgravity (0G) and modified gravity (i.e., hypergravity (1.8G) and modified gravity (Martian gravity)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Caen trials

Trials by the same sponsor.

NCT07406737 — Feasibility and Outcomes Registry of Lumenless dEfibrillation Leads for Conduction System Pacing · not yet recruiting
NCT06639750 — Respiratory Microbioma and Respiratory Complications After Hematopoietic Stem Cell Transplantion · not yet recruiting
NCT07467031 — Bachstim Registry: a Feasability Study of Bachmann's Area Pacing · not yet recruiting
NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
NCT07520578 — EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WI · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05531162 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Caen
Last refreshed: 25 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05531162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing